Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSolomon, Benjamin
dc.contributor.authorCallejo Perez, Ana
dc.contributor.authorBar, Jair
dc.contributor.authorBerchem, Guy
dc.contributor.authorBazhenova, Lyudmila
dc.contributor.authorSaintigny, Pierre
dc.contributor.authorFelip Font, Enriqueta
dc.date.accessioned2022-08-12T10:47:07Z
dc.date.available2022-08-12T10:47:07Z
dc.date.issued2022-07
dc.identifier.citationSolomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul;11(14):2790–800.
dc.identifier.issn2045-7634
dc.identifier.urihttp://hdl.handle.net/11351/8001
dc.descriptionGenòmica; Transcriptòmica; Càncer de pulmó
dc.description.sponsorshipThis work was supported by the ARC Foundation for Cancer Research, Villejuif, France and Worldwide Innovative Network (WIN) Association––WIN Consortium, Villejuif, France, sponsor of the study. WIN was responsible for the study design, collection, analysis, and interpretation of data as well as writing of the report. The study drugs were provided by Pfizer, as part of an alliance between Merck KGaA, Darmstadt, Germany and Pfizer. Funded in part by National Cancer Institute grant P30 CA023100 and the Joan and Irwin Jacobs Fund philanthropic fund (RK).
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesCancer Medicine;11(14)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleA WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/cam4.4635
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1002/cam4.4635
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Solomon B] Avera Cancer Institute, Sioux Falls, South Dakota, USA. [Callejo A, Felip E] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bar J] Chaim Sheba Medical Center, Tel Hashomer, Israel. [Berchem G] Centre Hospitalier de Luxembourg, Luxembourg Institute of Health, Luxembourg City, Luxemburg. [Bazhenova L] University of California San Diego, Moores Cancer Center, San Diego, California, USA. [Saintigny P] Centre Léon Bérard, Cancer Research Center of Lyon, University of Lyon, Lyon, France
dc.identifier.pmid35307972
dc.identifier.wos000776243800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple